Commission Implementing Regulation (EU) 2022/1107 of 4 July 2022 laying down common specifications for certain class D in vitro diagnostic medical devices in accordance with Regulation (EU) 2017/746 of the European Parliament and of the Council (Text with EEA relevance)

This Regulation lays down common specifications for certain class D in vitro diagnostic medical devices in respect of the requirements regarding the performance characteristics set out in Section 9.1, points (a) and (b), Section 9.3 and Section 9.4, point (a), of Annex I to Regulation (EU) 2017/746. Annex I lays down common specifications for devices covered by Annexes II to XIII, as specified in that Annex. Annex II lays down common specifications for devices intended for detection of blood group antigens in the ABO, Rh, Kell, Duffy and Kidd blood group systems. Annex III lays down common specifications for devices intended for detection or quantification of markers of human immunodeficiency virus (HIV) infection. Annex IV lays down common specifications for devices intended for detection or quantification of markers of human T-cell lymphotropic virus (HTLV) infection. Annex V lays down common specifications for devices intended for detection or quantification of markers of hepatitis C virus (HCV) infection. Annex VI lays down common specifications for devices intended for detection or quantification of markers of hepatitis B virus (HBV) infection. Annex VII lays down common specifications for devices intended for detection or quantification of markers of hepatitis D virus (HDV) infection. Annex VIII lays down common specifications for devices intended for detection of markers of variant Creutzfeldt-Jakob disease (vCJD). Annex IX lays down common specifications for devices intended for detection or quantification of markers of cytomegalovirus (CMV) infection. Annex X lays down common specifications for devices intended for detection or quantification of markers of Epstein-Barr virus infection (EBV). Annex XI lays down common specifications for devices intended for detection of markers of Treponema pallidum infection. Annex XII lays down common specifications for devices intended for detection or quantification of markers of Trypanosoma cruzi infection. Annex XIII lays down common specifications for devices intended for detection or quantification of markers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

For the purposes of this Regulation, the following definitions apply: (1) ‘true positive’ means a specimen known to be positive for the target marker and correctly classified by the device; (2) ‘false negative’ means a specimen known to be positive for the target marker and misclassified by the device; (3) ‘false positive’ means a specimen known to be negative for the target marker and misclassified by the device; (4) ‘the limit of detection’ (‘LOD’) means the smallest amount of the target marker that can be detected; (5) ‘nucleic acid amplification techniques’ (‘NAT’) means methods of detection and/or quantification of nucleic acids by either amplification of a target sequence, by amplification of a signal or by hybridisation; (6) ‘NAT system’ means the combination of devices used for extraction, amplification and detection of nucleic acids; (7) ‘rapid test’ means a qualitative or semi-quantitative in vitro diagnostic medical device, used singly or in a small series, which involves non-automated procedures (except the reading of results) and has been designed to give a fast result; (8) ‘robustness’ means the capacity of an analytical procedure to remain unaffected by small but deliberate variations in method parameters and provides an indication of its reliability during normal usage; (9) ‘cross-reactivity’ means the ability of non-target analytes or markers to cause false positive results in an assay because of similarity, e.g. the ability of non-specific antibodies binding to a test antigen of an antibody assay, or the ability of non-target nucleic acids to be reactive in a NAT assay; (10) ‘interference’ means the ability of unrelated substances to affect the results in an assay; (11) ‘whole system failure rate’ means the frequency of failures when the entire process is performed as prescribed by the manufacturer; (12) ‘first-line assay’ means a device used to detect a marker or analyte, and the use of which may be followed by the use of a confirmatory assay; devices intended solely to be used to monitor a previously determined marker or analyte are not considered first-line assays; (13) ‘confirmatory assay’ means a device used for the confirmation of a reactive result from a first line assay; (14) ‘supplemental assay’ means a device that is used to provide further information for the interpretation of the test result of another assay; (15) ‘virus typing device’ means a device used for typing with already known positive samples, not used for primary diagnosis of infection or for screening; (16) ‘95 % positive cut-off value’ means the analyte concentration where 95 % of test runs give positive results following serial dilutions of an international reference material, where available, e.g. a World Health Organisation (WHO) International Standard or reference material calibrated against the WHO International Standard.

1 From 25 July 2022 until 25 July 2024, devices that are in conformity with the common technical specifications set out in Decision 2002/364/EC shall be presumed to be in conformity with the requirements regarding the performance characteristics set out in Section 9.1, points (a) and (b), Section 9.3 and Section 9.4, point (a), of Annex I to Regulation (EU) 2017/746. During that period manufacturers of devices that are not in conformity with the common technical specifications set out in Decision 2002/364/EC shall duly justify that they have adopted solutions that ensure a level of safety and performance that is at least equivalent thereto.

2 From 25 July 2022 until 25 July 2024 devices that are in conformity with the common specifications set out in this Regulation shall be presumed to be in conformity with the requirements regarding the performance characteristics set out in Section 9.1, points (a) and (b), Section 9.3 and Section 9.4, point (a), of Annex I to Regulation (EU) 2017/746.

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union. It shall apply from 25 July 2024. However, Article 3 shall apply from 25 July 2022.